Skip to main content
. 2023 Jul 7;16(7):977. doi: 10.3390/ph16070977

Figure 16.

Figure 16

Illustrative brain karyopyknotic cell microscopic presentation (HE staining; magnification 400× (A–D), scale bar 100 μm; magnification 600× (E–P), scale bar 50 μm) in the sotalol BPC 157-treated rats assessed following application of sotalol, given therapy application at 15 min (A,E,I,M) (period 0–15 min), at 90 min (B,F,J,N) (period 0–90 min) and at 180 min (C,G,K,O) (period 0–180 min) or at 180 min (D,H,L,P) (period 90–180 min). BPC 157 medication was given as an early application at 5 min after sotalol (A,B,D,E,G,H), or as delayed post-treatment at 90 min sotalol-time and assessment at 180 min sotalol-time (D,H,L,P). No karyopyknotic cells were observed in all four areas of the brain (cerebrum, hippocampus, hypothalamus, and cerebellum) with early regimen at the end period of 15 min (A,E,I,M) (period 0–15 min), and delayed regimen at 180 min sotalol-time (D,H,L,P) (period 90–180 min). Hippocampus (E–H) and cerebellum showed no karyopyknotic cell (M–P) with early regimen at the end period of 90 min (period 0–90) and 180 min (period 0–180 min) sotalol-time. Rare karyopyknotic cells were found in the cerebrum (B,C) and hypothalamus (J,K) with an early regimen at the end period of 90 min (period 0–90) and 180 min (period 0–180 min) sotalol-time.